Browsing Tag
Viatris
17 posts
Biocon Biologics wraps up integration of former Viatris biosimilars business
Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, has announced the successful integration of the acquired biosimilars…
July 5, 2023
Biocon Biologics debuts biosimilar HULIO in US market
In a significant development for healthcare accessibility, Biocon Biologics Ltd (BBL), a subsidiary of Biocon, announced the availability…
July 4, 2023
Biocon Biologics wraps up $3.3bn acquisition of Viatris biosimilars unit
Biocon said that its subsidiary Biocon Biologics has wrapped up the previously announced $3.3 billion acquisition of the…
November 30, 2022
Can Unichem Laboratories’ FDA approval for generic Dilantin boost its US epilepsy drug portfolio?
Unichem Laboratories wins US FDA approval for its generic Dilantin capsules to treat seizures, expanding its US neurology portfolio.
October 17, 2022
Biocon Biologics to buy biosimilars business of Viatris for up to $3.3bn
Biocon Biologics Limited (BBL), a subsidiary of Indian biopharma company Biocon, has agreed to acquire the biosimilars business…
March 1, 2022
Biocon Biologics, Viatris launch interchangeable biosimilars in US
Biocon Ltd. said that its subsidiary — Biocon Biologics and Viatris have launched interchangeable biosimilars SEMGLEE (insulin glargine-yfgn)…
November 16, 2021
FTC grants conditional approval for Mylan’s acquisition of Upjohn: What this means for the pharma industry
The U.S. Federal Trade Commission (FTC) has granted conditional approval for Mylan’s acquisition of Upjohn, Pfizer’s off-patent branded…
October 31, 2020